pharmaphorum

FEBRUARY 21, 2022

Already making inroads as a treatment for HER2-positive breast cancer, AstraZeneca and Daiichi Sankyo’s Enhertu has now shown efficacy in tumours that express lower levels of HER2 – potentially making it an option for a much broader group of patients. It’s a key moment for the two companies, as expansion into HER2-low breast cancer has been held up as a key requirement for Enhertu (trastuzumab deruxtecan) if it is to achieve its multibillion-dollar sales expectations.

Chemotherapy 130

Chemotherapy Labelling 130

Pharma Times

FEBRUARY 24, 2022

No sign of significant negative effects on anxiety and wellbeing following pioneering Small Pharma trial

157

157

Outsourcing Pharma

FEBRUARY 24, 2022

In its latest diversity, equity and inclusion report, Global Genes offers insight into obstacles faced by rare-disease patients from minority communities.

105

105

Drug Channels

FEBRUARY 25, 2022

Today’s guest post comes from Jason Zemcik, Vice President of Patient Affordability at TrialCard. Jason discusses two approaches to address the CMS Final Rule on manufacturer coupons and Best Price: the pharmacy copay offer and direct reimbursement to the patient. He goes on to describe TrialCard’s reimbursement capability solutions. To learn more about TrialCard Pay and how to prepare your copay program for the future, register for Solving the Best Price and Co-Pay Challenge – A Framework for A

74

74

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

FEBRUARY 21, 2022

Bayer has claimed EU approval for Kerendia, its new drug for chronic kidney disease (CKD) in people with type 2 diabetes, as the company tries to build a role of the drug alongside rival therapies from AstraZeneca and Johnson & Johnson. The approval is based on the phase 3 FIDELIO-DKD trial, in which Kerendia (finerenone) reduced the risk of kidney disease progression or renal death by 18% when added to the highest tolerated dose of standard therapy.

Diabetes 118

Diabetes 118

Pharma Times

FEBRUARY 21, 2022

The UK government is urged to be more mindful of children and young people who have mental health issues, following the publication of the NHS Elective Recovery Plan

107

107

Drug Channels

FEBRUARY 22, 2022

On March 15, 2022, Drug Channels Institute will release The 2022 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. This report—our thirteenth edition—remains the most comprehensive, fact-based tool for understanding the entire U.S. drug pricing, reimbursement, and dispensing system. 12 chapters, 430+ pages, 216 exhibits, 800+ endnotes: There is nothing else available that comes close to this report.

Specialty Pharmacies 70

Specialty Pharmacies Drug Pricing Biosimilars Vaccines 70

pharmaphorum

FEBRUARY 22, 2022

A study has suggested people with epilepsy may show patterns of activity and behaviour on social media that could serve as an early warning signal for sudden death – a rare but much feared complication of the disease. The study was carried out in six individuals who suffered sudden unexpected death in epilepsy (SUDEP), with the researchers analysing hundreds of Facebook posts for each subject in the six months leading up to their death, with the consent of surviving family members.

108

108

Pharma Times

FEBRUARY 22, 2022

The European Commission finds that Servier committed a breach of competition over blood pressure drug

130

130

Outsourcing Pharma

FEBRUARY 24, 2022

The AI-centered genomics company is joining with Donât Forget Morgan, a group for patients with BPAN, to explore treatments for the neurodegenerative condition.

64

64

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

Drug Channels

FEBRUARY 24, 2022

Winter—or at least February—is almost over. Celebrate the imminent return of spring with our selection of noteworthy news from around the drug channel. In this issue: Mark Cuban! Novo Nordisk confronts the gross-to-net bubble CVS Health finally acknowledges its profits from the 340B program Plus, an update to my all-time favorite chart. P.S. Please join the nearly 13,500 consumers of my daily commentary and links to neat stuff at @DrugChannels on Twitter.

86

86

pharmaphorum

FEBRUARY 21, 2022

The clinical research industry has long struggled with participant diversity. One study found that only 5% of Black or Asian United Kingdom residents had ever participated in a clinical trial. A study of FDA-approved vaccine trials from 2011-2020 showed that 78% of participants were white, even though only 60% of the U.S. population was. . And then came COVID-19.

Vaccines 108

Vaccines Physician Offices Hospitals 108

Pharma Times

FEBRUARY 23, 2022

Researchers discovered that recipients experiencing an allergic response to second COVID vaccine dose are minimal

Vaccines 117

Vaccines 117

NY Times

FEBRUARY 25, 2022

The first checks could be cut in April. The money — from the nation’s three major pharmaceutical distributors and Johnson & Johnson — will be used for addiction treatment and prevention.

56

56

Outsourcing Pharma

FEBRUARY 21, 2022

On February 23, five days ahead of the day of rare-disease awareness, OSPâs Rare and Orphan Diseases webinar will share insights from top industry experts.

59

59

pharmaphorum

FEBRUARY 22, 2022

A study has revealed that current NHS guidelines on testing for genetic alterations linked to cancer could be missing around half of people carrying them, says a new study. The work by scientists at the Institute for Cancer Research (ICR) suggests that access to genetic testing should be made easier because the guidelines as drawn up “would have excluded many people who had ‘actionable’ genetic alterations that could raise their risk of cancer.” Cancer is not usually inhe

102

102

Pharma Times

FEBRUARY 22, 2022

Study involving 10,000 patients will investigate a range of potentially ground-breaking oral antivirals

116

116

Drug Patent Watch

FEBRUARY 25, 2022

Annual Drug Patent Expirations for PEPCID+AC Pepcid Ac is a drug marketed by J And J Consumer Inc and is included in three NDAs. It is available from two suppliers.…. The post New patent expiration for J And drug PEPCID AC appeared first on DrugPatentWatch - Make Better Decisions.

52

52

Pharma Marketing Network

FEBRUARY 25, 2022

“ Being more focused, more narrow in terms of the meeting objectives, making sure the right people are there, and making sure that you have quick hit type of interventions during the course of the week to keep track of status is serving us very well. I would suggest that even if and when things return to normal, a lot of those practices and a lot of those mindsets of ways of working will probably continue even after.” – Jeff Fayer, Novartis.

Communication 52

Communication 52

pharmaphorum

FEBRUARY 22, 2022

A virtual menopause clinic service developed by Bia Care is starting a randomised clinical trial within the NHS that will not only test how well it performs, but also attempt to tackle inequalities in women’s health. The trial has been announced shortly after Bia Care was awarded additional funding from the NHS to extend the rollout of its digital platform, which helps women book an appointment, have a group online consultation with a doctor, get a personalised plan for managing menopause

100

100

Pharma Times

FEBRUARY 21, 2022

Study reveals that many with an increased risk of cancer were excluded from the potential for monitoring

111

111

Drug Patent Watch

FEBRUARY 25, 2022

Annual Drug Patent Expirations for TAVALISSE Tavalisse is a drug marketed by Rigel Pharms Inc and is included in one NDA. There are fourteen patents protecting this drug. This drug…. The post New patent for Rigel Pharms drug TAVALISSE appeared first on DrugPatentWatch - Make Better Decisions.

52

52

Pharma Mirror

FEBRUARY 24, 2022

Taking care of your mental health can be affordable. All you will have to do is choose therapy options that fit in your budget. In this article, we have outlined the most affordable therapy options. While the options fall in the lower price range, they are all capable of delivering your expected results. The post Ways to Access Affordable Mental Health Services appeared first on Pharma Mirror Magazine.

52

52

pharmaphorum

FEBRUARY 23, 2022

Takeda has forged another alliance as it continues a push into gene therapy, agreeing a deal worth up to $2 billion with Code Biotherapeutics for opt-in rights to four candidates for rare diseases. The Japanese drugmaker will get access to Code Bio’s 3DNA non-viral genetic medicine delivery platform, initially for a liver-directed programme, and is also interested in deploying the technology for central nervous system disorders.

Immunity 98

Immunity Immunization 98

Pharma Times

FEBRUARY 25, 2022

Valneva expects to receive a positive CHMP recommendation for the conditional approval of its VLA2001 vaccine

Vaccines 108

Vaccines 108

Drug Patent Watch

FEBRUARY 25, 2022

Annual Drug Patent Expirations for PIFELTRO Pifeltro is a drug marketed by Msd Merck Co and is included in one NDA. It is available from one supplier. There is one…. The post New patent for Msd Merck drug PIFELTRO appeared first on DrugPatentWatch - Make Better Decisions.

52

52

Pharma Mirror

FEBRUARY 25, 2022

Cambridge, UK, Framingham, MA (USA), and Dijon, France, Abzena, a partner research organization for integrated services from discovery through to clinical and commercial manufacturing for biologics and bioconjugates, Alira Health, an international patient-centric and technology-enabled advisory firm whose mission is to humanize healthcare, and Oncodesign (ALONC -FR0011766229), a biopharmaceutical company dedicated to precision medicine, announce today that, with the launch of DRIVE™-Biologics,

52

52

pharmaphorum

FEBRUARY 23, 2022

Nothing quite compares to the level of solace patients find in connecting with others who share similar health experiences. These interactions have become so fundamental to people living with chronic conditions that a recent Health Union survey of 2,371 patients revealed 95% use online social resources for health reasons. In 2022, social health – the dynamic, real-time actions people take to find meaningful connections and share information throughout the health journey – is more relevant tha

94

94

Pharma Times

FEBRUARY 25, 2022

Figures by National Audit Office estimate that programme prevented up to 262,000 hospitalisations

Community Pharmacies 112

Community Pharmacies Vaccines 112

Drug Patent Watch

FEBRUARY 25, 2022

Annual Drug Patent Expirations for PEPCID+COMPLETE Pepcid Complete is a drug marketed by J And J Consumer Inc and is included in one NDA. It is available from four suppliers.…. The post New patent expiration for J And drug PEPCID COMPLETE appeared first on DrugPatentWatch - Make Better Decisions.

52

52

The Nutrition Pharmacist

FEBRUARY 23, 2022

For those of you who know me, or have had a consult, you know this is one of my favourite tools to help you best navigate your health and wellness! So, what is it all about? What results can you expect? And how can it guide your health and wellness journey? I’ve summarised all this in today’s blog post – I hope you find it useful. What is DNA testing?

52

52

pharmaphorum

FEBRUARY 24, 2022

The UK’s health research data capabilities are rapidly evolving. For example, during the height of the pandemic, NIHR’s integrated health research system was able to compare COVID-19 hospital caseloads to COVID-19 research activity in real time. This enabled rapid recruitment to multiple COVID-19 clinical trials throughout England/UK. . In a post-pandemic world, how can we use insights gained from healthcare and research activity data to inform commercial research planning and placement decisio

Hospitals 94

Hospitals 94

Pharma Times

FEBRUARY 23, 2022

New company Haleon will become standalone venture as GSK's strategy for the future unfolds

110

110

Drug Patent Watch

FEBRUARY 25, 2022

Annual Drug Patent Expirations for DOVATO Dovato is a drug marketed by Viiv Hlthcare and is included in one NDA. It is available from one supplier. There are two patents…. The post New patent for Viiv Hlthcare drug DOVATO appeared first on DrugPatentWatch - Make Better Decisions.

52

52

Pharma Mirror

FEBRUARY 19, 2022

HONG KONG, Global pandemic control is still facing enormous challenges after more than two years since the outbreak of the COVID-19. Following the Delta and Beta variants, Omicron variant emerged at the end of 2021, and its enhanced infectivity has cast a shadow over the global COVID-19 control. Recently, Omicron quickly spread in Japan and South Korea, and the number of newly confirmed cases in South Korea has exceeded 90,000 for two consecutive days.

Vaccines 52

Vaccines 52